6 completed, 2 active not recruiting, 2 unknown, 1 recruiting. 11 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Active not recruiting 2, Unknown 2, Recruiting 1 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Multiple Sclerosis, Secondary Progressive: new trials by email Literature Review of Multiple Sclerosis, Secondary Progressive trials Research Report on Multiple Sclerosis, Secondary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | Active not recruiting | Kyverna Therapeutics | 120 | 2024-09-20 | 2025-01-13 |
| Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). Cladribine Subcutaneous Injection, 0.9% Chloride Injection Sodium - Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis | Phase 2 / Phase 3 | Recruiting | Institute of Psychiatry and Neurology, Warsaw | 188 | 2022-10-03 | 2023-07-28 |
| Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis Extracorporeal Photopheresis, MS standard of care - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Completed | Abu Dhabi Stem Cells Center | 15 | 2022-03-26 | 2026-05-07 |
| Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis N-acetyl cysteine, Placebo - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 2 | Active not recruiting | Emmanuelle Waubant, MD PhD | 98 | 2022-02-16 | 2026-03-11 |
| Hydroxychloroquine and Indapamide in SPMS Hydroxychloroquine Pill, Indapamide Pill - Multiple Sclerosis, Secondary Progressive | Phase 2 | Unknown | University of Calgary | 35 | 2021-10-01 | 2022-05-18 |
| Phase II Clinical Trial of OCH-NCNP1 OCH-NCNP1, Placebo - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 2 | Completed | National Center of Neurology and Psychiatry, Japan | 30 | 2019-12-06 | 2023-11-09 |
| Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Insulin, Placebo (Sterile diluent) - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 105 | 2017-12-01 | 2023-03-10 |
| Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) Domperidone - Multiple Sclerosis, Secondary Progressive | Phase 2 | Completed | University of Calgary | 64 | 2015-02-01 | 2020-02-24 |
| Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Andrographolides, placebo - Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive | Phase 1 / Phase 2 | Unknown | Innobioscience SpA | 68 | 2014-09-01 | 2014-10-27 |
| Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis ibudilast, Placebo oral capsule - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | Completed | MediciNova | 255 | 2013-11-01 | 2020-07-28 |
| Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis Tovaxin Autologous T Cell Vaccine - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1 / Phase 2 | Completed | Opexa Therapeutics, Inc. | 16 | 2002-07-01 | 2017-01-11 |
Multiple Sclerosis, Chronic Progressive (11) · Multiple Sclerosis (4) · Multiple Sclerosis, Relapsing-Remitting (4) · Autoimmune Diseases (1)
Autoimmune Diseases of the Nervous System (11) · Chronic Disease (11) · Demyelinating Autoimmune Diseases, CNS (11) · Demyelinating Diseases (11) · Disease Attributes (11) · Immune System Diseases (11) · Nervous System Diseases (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Autoimmune Diseases (10) · Multiple Sclerosis (7)
Acetylcysteine (1) · Domperidone (1) · Hydroxychloroquine (1) · Indapamide (1) · Insulin (1) · Photochemotherapy (1) · Photopheresis (1) · andrographolide (1) · ibudilast (1) · neoandrographolide (1)
University of Calgary (2) · Abu Dhabi Stem Cells Center (1) · Emmanuelle Waubant, MD PhD (1) · Innobioscience SpA (1) · Institute of Psychiatry and Neurology, Warsaw (1) · Johns Hopkins University (1) · Kyverna Therapeutics (1) · MediciNova (1) · National Center of Neurology and Psychiatry, Japan (1) · Opexa Therapeutics, Inc. (1)
United States (5) · Canada (2) · Chile (1) · Japan (1) · Poland (1) · United Arab Emirates (1)
Ellen Mowry, MD, MCR (1) · Iwona Kurkowska-Jastrzebska, MD, PhD (1) · Jaye Thompson, PhD (1) · Juan L Hancke, DVM, PhD (1) · Marcus W Koch, MD, PhD (1) · Robert J Fox, MD, FAAN (1) · Scott Newsome, DO (1) · Tomoko Okamoto, MD (1) · Yendry Ventura Carmenate, M.D. (1)
PMID 30157388, PMID 32380977, PMID 33054533, PMID 34038379, PMID 36182028, PMID 37537928, PMID 38224478, PMID 39217272, PMID 41342004, PMID 41509523
U01NS082329 (1)